The malignant phenotype in breast cancer is driven by eIF4A1-mediated changes in the translational landscape

Human mRNA DeXD/H-box helicases are ubiquitous molecular motors that are required for the majority of cellular processes that involve RNA metabolism. One of the most abundant is eIF4A, which is required during the initiation phase of protein synthesis to unwind regions of highly structured mRNA that would otherwise impede the scanning ribosome. Dysregulation of protein synthesis is associated with tumorigenesis, but little is known about the detailed relationships between RNA helicase function and the malignant phenotype in solid malignancies. Therefore, immunohistochemical analysis was performed on over 3000 breast tumors to investigate the relationship among expression of eIF4A1, the helicase-modulating proteins eIF4B, eIF4E and PDCD4, and clinical outcome. We found eIF4A1, eIF4B and eIF4E to be independent predictors of poor outcome in ER-negative disease, while in contrast, the eIF4A1 inhibitor PDCD4 was related to improved outcome in ER-positive breast cancer. Consistent with these data, modulation of eIF4A1, eIF4B and PCDC4 expression in cultured MCF7 cells all restricted breast cancer cell growth and cycling. The eIF4A1-dependent translatome of MCF7 cells was defined by polysome profiling, and was shown to be highly enriched for several classes of oncogenic genes, including G-protein constituents, cyclins and protein kinases, and for mRNAs with G/C-rich 5′UTRs with potential to form G-quadruplexes and with 3′UTRs containing microRNA target sites. Overall, our data show that dysregulation of mRNA unwinding contributes to the malignant phenotype in breast cancer via preferential translation of a class of genes involved in pro-oncogenic signaling at numerous levels. Furthermore, immunohistochemical tests are promising biomarkers for tumors sensitive to anti-helicase therapies.

[1]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[2]  N. Colburn,et al.  Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis. , 2005, Cancer research.

[3]  Peter F. Stadler,et al.  Memory Efficient Folding Algorithms for Circular RNA Secondary Structures , 2006, German Conference on Bioinformatics.

[4]  R. Cencic,et al.  Modifying chemotherapy response by targeted inhibition of eukaryotic initiation factor 4A , 2013, Blood Cancer Journal.

[5]  J. Graff,et al.  eIF-4E expression and its role in malignancies and metastases , 2004, Oncogene.

[6]  Nicholas J Wareham,et al.  Allelic association of the human homologue of the mouse modifier Ptprj with breast cancer. , 2005, Human molecular genetics.

[7]  A. Eggermont,et al.  eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies , 2014, Nature.

[8]  Ernest Turro,et al.  Flexible analysis of RNA-seq data using mixed effects models , 2014, Bioinform..

[9]  R. Cencic,et al.  Antitumor Activity and Mechanism of Action of the Cyclopenta[b]benzofuran, Silvestrol , 2009, PloS one.

[10]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[11]  L. Coin,et al.  Haplotype and isoform specific expression estimation using multi-mapping RNA-seq reads , 2011, Genome Biology.

[12]  Hans-Peter Lenhof,et al.  GeneTrailExpress: a web-based pipeline for the statistical evaluation of microarray experiments , 2008, BMC Bioinformatics.

[13]  W. Sauerbrei,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.

[14]  N. Sonenberg,et al.  Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap , 1990, Nature.

[15]  I. Ellis,et al.  An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer , 2007, Genome Biology.

[16]  R. Spriggs,et al.  Translational Repression and eIF4A2 Activity Are Critical for MicroRNA-Mediated Gene Regulation , 2013, Science.

[17]  Daniel Rios,et al.  Ensembl 2011 , 2010, Nucleic Acids Res..

[18]  R. Jackson,et al.  The mechanism of eukaryotic translation initiation and principles of its regulation , 2010, Nature Reviews Molecular Cell Biology.

[19]  C. Burge,et al.  Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets , 2005, Cell.

[20]  E. Marcotte,et al.  Insights into the regulation of protein abundance from proteomic and transcriptomic analyses , 2012, Nature Reviews Genetics.

[21]  R. Göke,et al.  The tumour suppressor Pdcd4: recent advances in the elucidation of function and regulation , 2009, Biology of the cell.

[22]  P. Pharoah,et al.  Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates? , 2009, British Journal of Cancer.

[23]  J. Olson,et al.  PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. , 2009, Cancer research.

[24]  N. Sonenberg,et al.  eIF4B controls survival and proliferation and is regulated by proto-oncogenic signaling pathways , 2010, Cell cycle.

[25]  Gordon K Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .

[26]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Cole Trapnell,et al.  Ultrafast and memory-efficient alignment of short DNA sequences to the human genome , 2009, Genome Biology.

[28]  Päivi Heikkilä,et al.  Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies , 2010, PLoS medicine.

[29]  L. Chiriboga,et al.  Alterations in the expression of PDCD4 in ductal carcinoma of the breast. , 2007, Oncology reports.

[30]  N. Sonenberg,et al.  Control of Cell Survival and Proliferation by Mammalian Eukaryotic Initiation Factor 4B , 2010, Molecular and Cellular Biology.

[31]  N. Colburn,et al.  Tumorigenesis Suppressor Pdcd4 Down-Regulates Mitogen-Activated Protein Kinase Kinase Kinase Kinase 1 Expression To Suppress Colon Carcinoma Cell Invasion , 2006, Molecular and Cellular Biology.

[32]  Mikael Bodén,et al.  MEME Suite: tools for motif discovery and searching , 2009, Nucleic Acids Res..

[33]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[34]  C. Caldas,et al.  Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance , 2011, Breast Cancer Research.

[35]  Konstantinos J. Mavrakis,et al.  RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer , 2014, Nature.

[36]  V. Speirs,et al.  Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity , 2009, British Journal of Cancer.

[37]  C. Caldas,et al.  Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer , 2012, British Journal of Cancer.

[38]  Masato Katahira,et al.  A dimeric RNA quadruplex architecture comprised of two G:G(:A):G:G(:A) hexads, G:G:G:G tetrads and UUUU loops. , 2002, Journal of molecular biology.

[39]  M. Dyer,et al.  A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma , 2013, Leukemia.

[40]  C. Fraser,et al.  Human eIF4E promotes mRNA restructuring by stimulating eIF4A helicase activity , 2013, Proceedings of the National Academy of Sciences.

[41]  Jon R Lorsch,et al.  The mechanism of eukaryotic translation initiation: new insights and challenges. , 2012, Cold Spring Harbor perspectives in biology.

[42]  J. Pelletier,et al.  Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A , 2006, Nature chemical biology.

[43]  Tomoyuki Tsumuraya,et al.  Effects of hippuristanol, an inhibitor of eIF4A, on adult T-cell leukemia. , 2011, Biochemical pharmacology.

[44]  Carlos Caldas,et al.  Biological and prognostic associations of miR‐205 and let‐7b in breast cancer revealed by in situ hybridization analysis of micro‐RNA expression in arrays of archival tumour tissue , 2012, The Journal of pathology.

[45]  Simon Tavaré,et al.  beadarray: R classes and methods for Illumina bead-based data , 2007, Bioinform..

[46]  Mark J. Dunning,et al.  BASH: a tool for managing BeadArray spatial artefacts , 2008, Bioinform..

[47]  G. Mills,et al.  Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer , 2012, Breast Cancer Research.

[48]  M. Selbach,et al.  Global quantification of mammalian gene expression control , 2011, Nature.

[49]  Charles Elkan,et al.  Fitting a Mixture Model By Expectation Maximization To Discover Motifs In Biopolymer , 1994, ISMB.

[50]  K. Klempnauer,et al.  The transformation suppressor protein Pdcd4 shuttles between nucleus and cytoplasm and binds RNA , 2003, Oncogene.

[51]  D. Kufe,et al.  TARGETING THE eIF4A RNA HELICASE BLOCKS TRANSLATION OF THE MUC1-C ONCOPROTEIN , 2012, Oncogene.

[52]  Roger Y Tsien,et al.  Control of mammalian translation by mRNA structure near caps. , 2006, RNA.